Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656770 | 0.93 | SIGMAR1 (0.47) | SIGMAR1KCNH2ALDH1A1CNR1CNR2 | |
| SCHEMBL1356484 | 0.85 | SIGMAR1 (0.68) | SIGMAR1KCNH2MAPTKMT2A | |
| SCHEMBL1355084 | 0.84 | SIGMAR1 (0.70) | SIGMAR1KCNH2MAPTKMT2A | |
| SCHEMBL1357037 | 0.84 | SIGMAR1 (0.51) | SIGMAR1KCNH2ALDH1A1CNR1CNR2 | |
| SCHEMBL1356902 | 0.82 | SIGMAR1 (0.67) | SIGMAR1KCNH2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL4560695 | 0.80 | SIGMAR1 (0.52) | SIGMAR1KCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1354910 | 0.77 | SIGMAR1 (0.47) | SIGMAR1KCNH2ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4655482 | 0.76 | SIGMAR1 (0.51) | SIGMAR1KCNH2ALDH1A1CNR1CNR2 | |
| SCHEMBL1356858 | 0.76 | SIGMAR1 (0.64) | SIGMAR1KCNH2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1356745 | 0.71 | KDM4E (0.44) | SIGMAR1KCNH2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | claimed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | claimed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | claimed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | claimed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | claimed |
| EP-1994008-B1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | ESTEVE LABOR DR (ES) | 2016-08-10 | — | — | EP | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-8410159-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2013-04-02 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-11-17 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-7989485-B2 | Imidazole compounds having pharmaceutical activity towards the sigma receptor | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-08-02 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137560-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885KCNH2 639/4885ALDH1A1 519/4885 |
| US-20110281848-A1 | IMIDAZOLE COMPOUNDS HAVING PHARMACEUTICAL ACTIVITY TOWARDS THE SIGMA RECEPTOR | SIGMAR1, TMEM97, OPRK1 | SIGMAR1 1/4885KCNH2 639/4885ALDH1A1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.